Shared on30 Jul 25Fair value Increased 6.45%
The upward revision in Indoco Remedies’ price target is primarily driven by significantly improved forecasts for revenue growth and a higher expected future P/E, resulting in the consensus price target increasing from ₹244.25 to ₹260.00. What's in the News Indoco Remedies will hold a board meeting to consider and approve unaudited financial results for the quarter ended June 2025.
Shared on21 Jul 25Fair value Decreased 15%
Despite an improved revenue growth outlook, Indoco Remedies’ consensus price target has dropped notably as a declining future P/E signals reduced market confidence in the company's earnings quality, lowering fair value from ₹286.91 to ₹244.25. What's in the News Indoco's UK subsidiary launched Ticagrelor film-coated tablets 90mg in the UK, to be marketed and distributed by Clarity Pharma.
Shared on01 May 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on23 Apr 25Fair value Decreased 1.09%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Decreased 8.24%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on19 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on12 Mar 25Fair value Increased 21%
AnalystConsensusTarget has decreased future PE multiple from 13.8x to 11.4x.